Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
HYOR$0.07+0.00(+0.13%)HyOrc Unveils European Expansion Strategy, Targets 150 TPD Waste-to-Methanol Facility in Portugal by 2028[5:53:08 PM ET]AMGN$444.00+4.74(+1.08%)AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS Amgen (NASDAQ: AMGN) today announced the appointment of David W. Gibbs to its Board of Directors, effective immediately. Gibbs will serve on the...[5:52:00 PM ET]PPTA$16.48+0.04(+0.24%)Perpetua Resources Awarded Up to $40 Million in U.S. Army Funding to Advance Domestic Tungsten Supply for American Defense Perpetua Resources Corp. (Nasdaq: PPTA) (TSX: PPTA) ("Perpetua Resources" or "Perpetua" or the "Company") today announced a new 36-month, $40 million ...[5:45:00 PM ET]VLRS$5.89+0.21(+3.70%)Volaris Reports Financial Results for the Third Quarter 2026: $1 Billion Revenue, up 32% YoY[5:30:00 PM ET]BLX$53.37-0.54(-1.00%)BLADEX ANNOUNCES QUARTERLY DIVIDEND PAYMENT FOR THIRD QUARTER 2026 Bladex, Inc. announced today its Board of Directors' approval of a quarterly cash dividend of US$0.6875 per share corresponding to the third quarter...[5:30:00 PM ET]BLX$53.37-0.54(-1.00%)Bladex announces Net Profit of $63.2 Million for the Third Quarter 2026 Bladex, Inc. (NYSE: BLX, or "the Bank"), a Panama-based multinational bank originally established by the central banks of 23 Latin-American and...[5:30:00 PM ET]BLSH$27.60-0.61(-2.16%)Issuer Sponsored Token Coalition gains momentum as QRT, Vertalo and zerohash join[5:30:00 PM ET]AMYZF$0.03-0.00(-0.65%)RecycLiCo Announces Filing and Mailing of Management Information Circular for 2026 Annual General Meeting[5:24:21 PM ET]CERO$0.01+0.00(+25.00%)CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies[5:21:39 PM ET]ACNT$13.53-0.41(-2.94%)CORRECTING and REPLACING Ascent Industries Sets Third Quarter 2026 Earnings Conference Call for November 4, 2026, at 5:00 p.m. ET[5:20:00 PM ET]NRG$93.61+1.30(+1.41%)NRG Energy to Report Third Quarter 2026 Financial Results on November 9, 2026[5:17:00 PM ET]TWFG$29.03+0.74(+2.62%)TWFG, Inc. To Announce Third Quarter 2026 Financial Results on Wednesday, November 4, 2026[5:16:14 PM ET]AWK$141.70-1.05(-0.74%)New Jersey American Water and American Water Charitable Foundation Celebrate Completion of Rutgers Weather Station The American Water Charitable Foundation, a philanthropic non-profit organization established by American Water (NYSE: AWK), the largest regulated...[5:15:00 PM ET]VRT$203.01+8.69(+4.47%)Vertiv Simplifies High-Density AI Infrastructure Deployment Across Data Center Environments Vertiv Holdings Co. (NYSE: VRT), a global leader in critical digital infrastructure, today introduced the Vertiv™ SmartIT solution, a pre-engineered...[5:12:00 PM ET]CEFC$15.700.00(0.00%)Commercial National Financial Corporation Reports 3rd Quarter 2026 Results[5:10:52 PM ET]

ONCO · NASDAQ

Onconetix, Inc.

$0.32 -0.10 (-23.44%)

Company overview

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once-daily pill combining finasteride and tadalafil for treating benign prostatic hyperplasia. It is also developing a Streptococcus pneumoniae vaccine candidate designed to prevent middle ear infections in children and pneumonia in the elderly, as well as a universal flu vaccine providing protection against all virulent strains. Additionally, Onconetix has licensed a novel norovirus S&P nanoparticle virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.1M
Employees
12
Headquarters
Cincinnati, OH
Website
onconetix.gcs-web.com
CEO
David Allan White
Listed
February 18, 2022
P/E
-0.04
Dividend yield
0.00%

Company financials

Revenue
$735,198
Gross profit
$585,426
Operating income
-$6.8M
EBITDA
-$6.8M
Net income
-$9.7M
EPS
-$8.82
Total assets
$14.8M
Total debt
$289,922
Gross margin
79.63%
Net margin
-1,319.55%
Earnings yield
-2,754.91%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

0.062.224.376.528.68
ONCO 1D NASDAQ O0.43H0.43L0.40C0.42+0.01 (+2.75%)Vol572.99K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ONCOOnconetix, Inc. Press release Onconetix Announces Reverse Stock Split GlobeNewswire
ONCOOnconetix, Inc. Press release Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition GlobeNewswire
ONCOOnconetix, Inc. Press release Realbotix Announces Additional Draw under Bridge Loan from Onconetix Business Wire
ONCOOnconetix, Inc. Stock news Alnylam Pharmaceuticals (NASDAQ:ALNY) and Onconetix (NASDAQ:ONCO) Critical Comparison Defense World
ONCOOnconetix, Inc. Stock news Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket Benzinga
ONCOOnconetix, Inc. Press release SRX Global Provides Shareholders with Update on Liquidation GlobeNewswire
ONCOOnconetix, Inc. Press release CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition GlobeNewswire
ONCOOnconetix, Inc. Press release Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition GlobeNewsWire
ONCOOnconetix, Inc. Stock news Realbotix LLC Announces Bridge Loan from Onconetix Business Wire
ONCOOnconetix, Inc. Press release Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events GlobeNewswire
ONCOOnconetix, Inc. Press release Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series GlobeNewsWire
ONCOOnconetix, Inc. Press release Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG GlobeNewsWire
ONCOOnconetix, Inc. Press release Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation GlobeNewsWire
ONCOOnconetix, Inc. Stock news Realbotix Provides Update on Nasdaq Listing GuruFocus
ONCOOnconetix, Inc. Press release Onconetix, Inc. Announces 1-for-10 Reverse Stock Split GlobeNewsWire
ONCOOnconetix, Inc. Press release Realbotix Provides Update on Nasdaq Listing Business Wire
ONCOOnconetix, Inc. Stock news Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving? Benzinga
ONCOOnconetix, Inc. Press release Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study GlobeNewsWire
ONCOOnconetix, Inc. Press release Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study Globe News Wire
ONCOOnconetix, Inc. Press release Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson GlobeNewsWire
See more
FAQ

Questions about Onconetix, Inc.

What does Onconetix, Inc. do?
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once-daily pill combining finasteride and tadalafil for treating benign prostatic hyperplasia. It is also developing a Streptococcus pneumoniae vaccine candidate designed to prevent middle ear infections in children and pneumonia in the elderly, as well as a universal flu vaccine providing protection against all virulent strains. Additionally, Onconetix has licensed a novel norovirus S&P nanoparticle virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
What is ONCO's market cap?
Onconetix, Inc. (ONCO) is a listed stock with a live quote. The latest market cap on this page is $1.1M.
Where is Onconetix, Inc. headquartered?
Onconetix, Inc. is headquartered in Cincinnati, OH.
How do I get ONCO news from the API?
Call GET /v1/news?tickers=ONCO. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ONCO news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ONCO, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ONCO price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs